Inclusive of all taxes
MYTERA 250 MG (Abiraterone Acetate Tablets) is a prescription pharmaceutical product specifically formulated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Each tablet contains 250 mg of Abiraterone Acetate, a potent selective inhibitor of CYP17 enzyme, instrumental in androgen production inhibition. By targeting androgen biosynthesis, MYTERA effectively decreases levels of testosterone and other androgens that promote prostate cancer cell growth. MYTERA 250 MG is typically prescribed in combination with a corticosteroid like prednisone to counteract potential side effects related to mineralocorticoid excess. These tablets are intended strictly for adult male patients under oncologist supervision, ensuring precision dosage and monitoring due to its critical therapeutic application. The formulation undergoes rigorous quality control to meet pharmaceutical standards, supporting efficacy in slowing disease progression and improving patient outcomes in advanced prostate cancer.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Abiraterone Acetate 250 mg per tablet |
| Therapeutic Use | Treatment of metastatic castration-resistant prostate cancer (mCRPC) |
| Mechanism of Action | Inhibits CYP17 enzyme to block androgen production |
| Dosage Form | Oral tablets |
| Combination Therapy | Administered with corticosteroids (e.g., prednisone) |
| Target Patient Group | Adult male patients with advanced prostate cancer |
| Manufacturer Quality | Complies with pharmaceutical-grade manufacturing standards |
| Regulatory Approval | Requires prescription and oncologist supervision |
| Packaging | Blister pack or bottle, depending on manufacturer |
| Storage Conditions | Store in a cool, dry place away from sunlight |
| Attributes | Description |
|---|---|
| Dosage Strength | 250 mg |
| Formulation Type | Film-coated tablet |
| Pharmacological Class | Androgen biosynthesis inhibitor |
| Therapeutic Area | Oncology - Prostate Cancer |
| Administration Route | Oral |
| Shelf Life | Typically 24 months from manufacture |
| Packaging Size | Available in packs of 30 tablets |
| Storage Temperature | 15°C to 30°C |
| Regulatory Category | Prescription Medication |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
MYTERA 250 MG is specifically approved for metastatic castration-resistant prostate cancer and is not indicated for early-stage prostate cancer treatment.
No, MYTERA 250 MG treatment requires concurrent administration of corticosteroids like prednisone to manage side effects related to mineralocorticoid excess.
Store MYTERA 250 MG tablets at temperatures between 15°C and 30°C, in a dry place away from direct sunlight and moisture to maintain drug stability.
Yes, patients should be regularly monitored for liver function, blood pressure, and potassium levels due to potential adverse effects associated with Abiraterone therapy.
MYTERA 250 MG inhibits the CYP17 enzyme critical in androgen biosynthesis, thus reducing testosterone levels that fuel prostate cancer cell growth.
Inclusive of all taxes
You Save: 0
